Nice! Their patent portfolio alone should value this well over $100 million market cap. Compare to other clinical stage biopharma stocks like Myovant and Tarsus trading on NYSE and Nasdaq. Vyome has a larger patent portfolio than both of those companies. Expecting a massive move toward a proper valuation when all comes to light.